tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Myelitis D009187 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Arm Injuries D001134 1 associated lipids
Intussusception D007443 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Oral Ulcer D019226 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Epididymitis D004823 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Porokeratosis D017499 1 associated lipids
Lentigo D007911 1 associated lipids
Mutism D009155 1 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dysuria D053159 1 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Akinetic Mutism D000405 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Orchitis D009920 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Priapism D011317 1 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Lacerations D022125 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Scheel AK et al. Severe neurotoxicity of tacrolimus (FK506) after renal transplantation: two case reports. 2001 Nov-Dec Transplant. Proc. pmid:11750573
Morris-Stiff G et al. Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. 1998 Transplant. Proc. pmid:9636525
Woodle ES et al. Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group. 1998 Transplant. Proc. pmid:9636526
Kumai Y et al. Reversible Cerebral Vasoconstriction Syndrome After Heart Transplantation: A Case Report. 2017 Transplant. Proc. pmid:29198694
Montejo M et al. Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+/R-) liver transplant recipients: a single-center experience. 2009 Jul-Aug Transplant. Proc. pmid:19715869
Barrera-Pulido L et al. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications. 2009 Jul-Aug Transplant. Proc. pmid:19715870
Burke GW et al. Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK 506 immunosuppression. 1998 Transplant. Proc. pmid:9532153
Büsing M et al. Mycophenolate mofetil/tacrolimus/single-shot versus azathioprine/cyclosporine/ATG in pancreas-kidney transplantation: results of a prospective randomized single-center study. 1998 Transplant. Proc. pmid:9532155
Bechstein WO et al. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. 2013 Jul-Aug Transplant. Proc. pmid:23953523
Tsang WK et al. Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients. 2000 Transplant. Proc. pmid:11119921
Gunji Y et al. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. 1993 Transplant. Proc. pmid:7679841
Ericzon BG et al. Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. 1991 Transplant. Proc. pmid:1721273
Gregory CR et al. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 1993 Transplant. Proc. pmid:7679842
Jain AB et al. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. 1991 Transplant. Proc. pmid:1721274
McMichael J et al. Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 1991 Transplant. Proc. pmid:1721275
Namii Y et al. Tetrahydropyranyladriamycin with FK 506 combination therapy for hamster-to-rat-concordant xenotransplantation. 1996 Transplant. Proc. pmid:8623358
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Valdivia LA et al. Prolonged survival of hearts obtained from chimeric donors in a mouse to rat xenotransplant model. 1996 Transplant. Proc. pmid:8623371
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Nalesnik MA et al. The effect of FK 506 and CyA on the Lewis rat renal ischemia model. 1990 Transplant. Proc. pmid:1689911
Mazali FC et al. Posttransplant diabetes mellitus: incidence and risk factors. 2008 Transplant. Proc. pmid:18455010
Lopes CT et al. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice. 2008 Transplant. Proc. pmid:18455036
Chan KL et al. Porcine small bowel transplantation with FK506 as a single immunosuppressant. 2001 Transplant. Proc. pmid:11406260
Platz KP et al. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. 1998 Transplant. Proc. pmid:9636596
Egawa H et al. Lymphoproliferative disorders in patients undergoing living-related liver transplantation. 1998 Transplant. Proc. pmid:9474982
Tellis V et al. No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation. 2005 Transplant. Proc. pmid:15848571
Uchida H et al. Chronopharmacology of tacrolimus in rats: toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile. 1999 Transplant. Proc. pmid:10578276
Akbas SH et al. Evaluation of the new EMIT tacrolimus assay in kidney and liver transplant recipients. 2004 Jan-Feb Transplant. Proc. pmid:15013308
Rosborough SL et al. Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. 1991 Transplant. Proc. pmid:1721306
Moffatt SD et al. Comparative efficacy of liposomal FK 506 with FK 506 (tacrolimus) with and without anti-CD4/CD8 monoclonal antibodies. 1999 Transplant. Proc. pmid:10578277
Zeevi A et al. In vitro assessment of FK 506 immunosuppressive activity in transplant patients. 1991 Transplant. Proc. pmid:1721307
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Woo J et al. Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. 1990 Transplant. Proc. pmid:1697113
Choi SJ et al. Tacrolimus-induced apoptotic signal transduction pathway. 2008 Transplant. Proc. pmid:18929848
Hoshinaga K et al. Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants. 2005 Transplant. Proc. pmid:15919457
Yoshimura N et al. Safety analysis after tacrolimus immunosuppression in renal transplant recipients in Japan: 5-year results in >1500 patients. 2005 Transplant. Proc. pmid:15919458
Takaori K et al. Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. 1992 Transplant. Proc. pmid:1376531
Kuroki H and Ikuta Y Nerve regeneration of vascularized rat limb allograft and functional recovery of long-term graft survivals treated by short course of FK 506 or cyclosporine. 1995 Transplant. Proc. pmid:7533405
Shaw BW et al. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. 1991 Transplant. Proc. pmid:1721338
Junge G et al. Microchimerism in patients after orthotopic liver transplantation: a prognostic indicator? 2002 Transplant. Proc. pmid:12176475
Böttiger Y et al. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. 2002 Transplant. Proc. pmid:12176476
Yuan-Xin L et al. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China. 2010 Jan-Feb Transplant. Proc. pmid:20172275
Kilian K et al. FK-506 (tacrolimus) therapy for an unusual SLE-like disease. 1998 Transplant. Proc. pmid:9865322
Schorlemmer HU and Kurrle R Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival. 1998 Transplant. Proc. pmid:9865337
Marqués E et al. Development of lymphoproliferative disease after liver transplantation. 2008 Transplant. Proc. pmid:19010169
Sánchez-Pérez B et al. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients. 2008 Transplant. Proc. pmid:19010171
Perego C et al. Orthotopic liver-small bowel transplantation in pigs: study of immunologic parameters during therapy with FK 506-based immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907908
Alessiani M et al. Combined FK 506 and mycophenolate mofetil immunosuppression prolongs survival after small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907922
Hayakawa K et al. Involvement of clonal deletion in immunotolerance induction: tests of Tacrolimus administration in rat renal transplantation. 1994 Transplant. Proc. pmid:7520608
Yoshimura R et al. Study of the effect of immunosuppressive agents on renal cytochrome P-450 system in the rat. 1994 Transplant. Proc. pmid:7520610
Fries D et al. Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. 1991 Transplant. Proc. pmid:1721370
Jain AB et al. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1703354
Wijnen RM et al. Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. 1991 Transplant. Proc. pmid:1721371
Moreno JM et al. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. 2003 Transplant. Proc. pmid:12962831
Venkataramanan R et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1703355
Shapiro R et al. A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. 2002 Transplant. Proc. pmid:12176521
Nishimura Y et al. A trial to obtain donor-specific immunotolerance using a vascularized thymus allograft. 1998 Transplant. Proc. pmid:9838684
Damotte D et al. Morphologic features of large bowel biopsies in combined small and large bowel transplantations could predict clinical rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083252
Zmonarski S et al. Expression of PBMC TLR4 in Renal Graft Recipients Who Experienced Delayed Graft Function Reflects Dynamic Balance Between Blood and Tissue Compartments and Helps Select a Problematic Patient. Transplant. Proc. pmid:30056893
Akutsu N et al. Two cases of calcineurin inhibitor-associated reversible posterior leukoencephalopathy syndrome in renal transplant recipients. 2008 Transplant. Proc. pmid:18790253
Ota H et al. Intrathymic microchimerism predicts rejection response in allograft recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123279
Kiuchi T et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. 1996 Transplant. Proc. pmid:8962229
Arita S et al. Effect of FK 506 in experimental pancreas transplantation. 1995 Transplant. Proc. pmid:7536980
Bunnapradist S and Takemoto SK Controlling treatment allocation bias in a registry analysis when comparing calcineurin inhibitors. 2003 Transplant. Proc. pmid:14611971
Balbontin FG et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. 2003 Transplant. Proc. pmid:14611982
Viebahn R et al. Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721401
Sato K et al. Effectiveness of triple drug immunosuppression for pancreaticoduodenal allotransplantation in dogs. 1992 Transplant. Proc. pmid:1379753
Masaki Y et al. Microchimerism and rat small bowel transplantation combined with donor-type bone marrow cells. 1996 Transplant. Proc. pmid:8769154
Murphy MP and Morris RE Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. 1993 Transplant. Proc. pmid:7685955
Kobayashi C et al. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. 1989 Transplant. Proc. pmid:2468254
Salizzoni M et al. Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation. 2001 Transplant. Proc. pmid:11377521
El Haggan W et al. One year evolution of bone mineral density in kidney transplant recipients receiving tacrolimus versus cyclosporine. 2002 Transplant. Proc. pmid:12176589
Langrehr JM et al. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563. 2001 Transplant. Proc. pmid:11377531
Tanabe K et al. Prospective analysis of thrombotic microangiopathy after renal transplantation: comparison between cyclosporine and tacrolimus immunosuppression. 2002 Transplant. Proc. pmid:12176590
Ishibashi M et al. Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max). 2001 Feb-Mar Transplant. Proc. pmid:11266958
Erickson LM et al. Gene expression profiles of rat heart allografts with immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11266960
Cai W et al. Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. 2018 Transplant. Proc. pmid:29735215
Gibelli NE et al. Sirolimus in pediatric liver transplantation: a single-center experience. 2009 Transplant. Proc. pmid:19376384
Van Buren D et al. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients. 1998 Transplant. Proc. pmid:9723299
Peeters P et al. Economic evaluation of Neoral versus Sandimmune maintenance therapy for de novo liver transplant patients: results from an International Randomized Controlled Trial. Milton Study Group. 1998 Transplant. Proc. pmid:9723301
Zhang J et al. Chemotherapy for De Novo Gastric Adenocarcinoma After Deceased Orthotopic Liver Transplantation: A Case Report. Transplant. Proc. pmid:28104131
Eun SC et al. Prolongation of the rat composite tissue allograft survival by the combination of tolerogenic immature dendritic cells and short-term treatment with FK506. 2013 Transplant. Proc. pmid:23769045
Kawano K et al. FK506 reduces oxidative hepatic injury following cold ischemic preservation and transplantation. 1996 Transplant. Proc. pmid:8658938
Wu GD et al. FK 506 inhibits the development of transplant arteriosclerosis. 1991 Transplant. Proc. pmid:1721433
Todo S et al. Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. 1987 Transplant. Proc. pmid:2445076
Liu W et al. Transfusion of endothelial cells with lentivirus-mediated expression of fas ligand prolonged survival of rat liver allograft. 2012 Transplant. Proc. pmid:22664023
Matevossian E et al. Nitric oxide inhibition and consecutive Aspisol application show a prolonged survival of orthotopic transplanted livers in a rat model. 2008 Transplant. Proc. pmid:18555092
Moreno M et al. Clinical management of tacrolimus drug interactions in renal transplant patients. 1999 Transplant. Proc. pmid:10500564
Tur MD et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. 2000 Transplant. Proc. pmid:11134804
Bahra M et al. Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage. 2002 Transplant. Proc. pmid:12431663
Hesse CJ et al. Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. 2002 Transplant. Proc. pmid:12431679
Preston R et al. FK 506 as primary immunosuppressive therapy in renal transplantation. 1998 Transplant. Proc. pmid:9636493
Guleria S et al. Tacrolimus (Pan Graf) as de novo therapy in renal transplant recipients in India. 2006 Transplant. Proc. pmid:16979989
Teng D et al. Comparison of rapamycin versus FK506 on expression of cytoprotective genes in the rat kidney allografts undergoing chronic allograft nephropathy. 2006 Transplant. Proc. pmid:16980034
Socci C et al. Pancreata from pediatric donors restore insulin independence in adult insulin-dependent diabetes mellitus recipients. 2010 Jul-Aug Transplant. Proc. pmid:20692410
White SA et al. Effect of acute rejection on expression of fibrosis associated genes in renal transplant recipients. 2000 Transplant. Proc. pmid:10700949
Martins L et al. Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity? 2004 Transplant. Proc. pmid:15194300
Groth CG Immunosuppressive regimens of tomorrow. 1995 Transplant. Proc. pmid:8539797
Braun F et al. Living-related versus living-unrelated kidney transplantation using tacrolimus initial immunosuppression. 2000 Transplant. Proc. pmid:10700989
Jiang H et al. Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703702